Bluebird bio Net Income

Bluebird bio (BLUE) currently reports a net income of $-200M as of March 2025. That compares with $-300M in the prior-year period — up 34.0% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Bluebird bio's net income history and peer comparisons.

Bluebird bio's net income increased from $-300M to $-200M — a 34.0% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bluebird bio's net income of $-200M is lower than the Healthcare sector average of $17B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Bluebird bio reported $-200M in net income as of March 2025. That compares with $-300M in the prior-year period — up 34.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-200M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Bluebird bio, and consider following BLUE for alerts when major investors trade the stock.